LNAI Stock Chart & Stats
$0.35
--
Market closed
$0.35
--
Day’s Range― - ―
52-Week Range$1.01 - $28.81
Previous CloseN/A
VolumeN/A
Average Volume (3M)7.74M
Market Cap
$14.51M
Enterprise Value$16.39M
Total Cash (Recent Filing)$3.16M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.58
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-61.25
Shares Outstanding4,533,890
10 Day Avg. Volume5,322,617
30 Day Avg. Volume7,737,401
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.76
Price to Sales (P/S)0.00
P/FCF Ratio-4.78
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue782.72
Enterprise Value/Gross Profit-217.00
Enterprise Value/Ebitda-0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lunai Bioworks News
LNAI FAQ
What was Lunai Bioworks’s price range in the past 12 months?
Lunai Bioworks lowest stock price was $1.01 and its highest was $28.81 in the past 12 months.
What is Lunai Bioworks’s market cap?
Lunai Bioworks’s market cap is $14.51M.
When is Lunai Bioworks’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lunai Bioworks’s earnings last quarter?
Currently, no data Available
Is Lunai Bioworks overvalued?
According to Wall Street analysts Lunai Bioworks’s price is currently Overvalued.
Does Lunai Bioworks pay dividends?
Lunai Bioworks does not currently pay dividends.
What is Lunai Bioworks’s EPS estimate?
Lunai Bioworks’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lunai Bioworks have?
Lunai Bioworks has 4,533,890 shares outstanding.
What happened to Lunai Bioworks’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lunai Bioworks?
Currently, no hedge funds are holding shares in LNAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lunai Bioworks
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Technical Analysis
Daré Bioscience
―
Akari Therapeutics
―
Collplant Holdings
―
―
Neurosense Therapeutics Ltd.
―
Ownership Overview
―
Insiders
2.60% Mutual Funds
― Other Institutional Investors
97.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---